tiprankstipranks
Trending News
More News >
ImmunityBio (IBRX)
NASDAQ:IBRX
US Market

ImmunityBio (IBRX) Financial Statements

Compare
1,715 Followers

ImmunityBio Financial Overview

ImmunityBio's market cap is currently $2.17B. The company's EPS TTM is $-0.07; its P/E ratio is -5.33; ImmunityBio is scheduled to report earnings on November 4, 2025, and the estimated EPS forecast is $-0.11. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue$ 14.74M$ 622.00K$ 240.00K$ 934.00K$ 605.00K
Gross Profit$ 14.74M$ 622.00K$ 240.00K$ 934.00K$ 605.00K
Operating Income$ -344.18M$ -362.25M$ -351.30M$ -330.28M$ -220.88M
EBITDA$ -264.43M$ -478.66M$ -351.88M$ -320.75M$ -204.22M
Net Income$ -413.56M$ -583.20M$ -416.57M$ -346.79M$ -221.85M
Balance Sheet
Cash & Short-Term Investments$ 149.81M$ 266.46M$ 107.18M$ 317.12M$ 96.06M
Total Assets$ 382.93M$ 504.45M$ 362.36M$ 468.91M$ 221.38M
Total Debt$ 504.17M$ 726.72M$ 723.77M$ 645.66M$ 275.55M
Net Debt$ 360.74M$ 461.27M$ 619.13M$ 464.56M$ 240.63M
Total Liabilities$ 871.06M$ 1.09B$ 812.18M$ 712.82M$ 339.87M
Stockholders' Equity$ -489.10M$ -586.99M$ -447.33M$ -242.17M$ -119.81M
Cash Flow
Free Cash Flow$ -398.12M$ -397.34M$ -415.67M$ -307.98M$ -173.39M
Operating Cash Flow$ -391.24M$ -366.76M$ -337.51M$ -274.42M$ -171.72M
Investing Cash Flow$ -12.25M$ -30.47M$ 27.30M$ -84.89M$ -19.81M
Financing Cash Flow$ 281.63M$ 558.34M$ 233.61M$ 505.44M$ 150.68M
Currency in USD

ImmunityBio Earnings and Revenue History

ImmunityBio Debt to Assets

ImmunityBio Cash Flow

ImmunityBio Forecast EPS vs Actual EPS